Catecholamine Biosynthesis and Dopamine Signalling
Catecholamine biosynthesis (L-Phe → L-Tyr (PAH; BH4) → L-DOPA (TH; tyrosine hydroxylase; rate-limiting; Fe2+/BH4/O2; Tyr + O2 + BH4 → L-DOPA + BH2 + H2O; Fe3+ at rest → Fe2+ active; BH4 regeneration: DHFR BH2→BH4; AADC (aromatic L-amino acid decarboxylase; PLP/B6; L-DOPA → DA) → dopamine (DA); DA → NE (DBH; dopamine β-hydroxylase; Cu2+/ascorbate; vesicular; NET → norepinephrine) → Epi (PNMT; SAM → NE → epinephrine; adrenal)); DA signalling: D1/D5 (Gs → cAMP → PKA → DARPP-32 Thr34 → PP-1 inhibition → AMPA/NMDA potentiation; prefrontal cortex working memory), D2/D3/D4 (Gi → ↓cAMP; β-arrestin → ERK1/2 ↓ haloperidol/clozapine targets); DA catabolism: MAO-B (monoamine oxidase B; outer mitochondrial membrane; DA → DOPAL + H2O2 (neurotoxic); selegiline/rasagiline inhibitors) + COMT (catechol-O-methyltransferase; SAM methyl donor; DA → 3-MT; HVA (homovanillic acid) final product); DA storage: VMAT2 (vesicular monoamine transporter 2; proton gradient → DA vesicular sequestration; protects cytoplasmic DA from MAO-B); DA reuptake: DAT (dopamine transporter; SLC6A3; Na+/Cl−-dependent); Parkinson disease: nigrostriatal DA neuron loss (α-synuclein aggregation; Lewy bodies; oxidative stress; mitochondrial dysfunction Complex I ↓; neuroinflammation NLRP3/NF-κB).
Spirulina Mechanisms in Dopamine/Catecholamine Biology
Tyrosine/TH BH4/Fe2+ Cofactor Support
TH (tyrosine hydroxylase; THOX1 isoform primary in CNS; rate-limiting catecholamine synthesis; TH activity depends on: (1) BH4 (Km ~10 µM; GTPCH1 → BH4 de novo; DHFR BH2→BH4 recycling; BH4 deficiency → TH ↓ → Parkinson risk amplification; BH4 shared with TPH1/2 and eNOS); (2) Fe2+ (catalytic site Fe2+; Fe3+ resting → O2 → Fe4+=O oxo-ferryl intermediate → BH4 radical → TH active; Fe chelation by excess iron: neurotoxic; Fe deficiency: TH activity ↓)); (3) Tyr substrate (Km ~100 µM; plasma Tyr ~60–120 µM; Tyr from Phe (PAH/BH4) or dietary; Tyr:LNAA ratio at BBB determines brain Tyr uptake (same LNAA transporter competition as Trp)); spirulina Tyr support: (~2.8 g Tyr/100g protein; 5g spirulina ~140 mg Tyr; plasma Tyr +5–10% vs. baseline in Tyr-limited subjects); BH4 maintenance: Nrf2 → DHFR +20–30% → BH2→BH4 regeneration (BH4 +10–20% in oxidatively stressed neurons); Fe2+ balance: spirulina phytoferritin/phytochelate provision (moderate; insufficient to cause iron overload; maintains non-haem Fe2+ pool for TH active site; transferrin saturation <70%); B6 (AADC PLP cofactor; 0.3–0.4 mg/100g; L-DOPA → DA conversion).
Nrf2/DJ-1/HO-1 Dopaminergic Neuroprotection
Dopaminergic neuron vulnerability (SNc (substantia nigra pars compacta); highest ROS exposure in brain: (1) DA auto-oxidation (DA → DA-quinone + O2•−; enzymatic: MAO-B → H2O2; non-enzymatic: DA + Fe3+ → semiquinone + OH•); (2) High mitochondrial density + Complex I vulnerability; (3) Low catalase relative to SOD → H2O2 accumulates; (4) α-Synuclein (SNCA) ROS sensitivity (oxidised α-Syn → aggregation nuclei → Lewy bodies; DA-quinone → SNCA Tyr39/75 oxidation → oligomerisation); (5) Iron accumulation (SNc has highest brain iron; Fe2+/Fenton → •OH)): spirulina neuroprotection: (1) Nrf2 (phycocyanobilin → Keap1-Cys → Nrf2 → HO-1 +35–50%, NQO1 +25–40%, SOD2 +20–30%, GSH +20–40% in SH-SY5Y dopaminergic cell models); (2) DJ-1 (PARK7; Cys106 oxidation-sensing; DJ-1 protects PTEN from oxidation → Akt survival; spirulina Nrf2 → DJ-1 +10–20% (DJ-1 has ARE in promoter)); (3) PINK1/Parkin mitophagy (AMPK → ULK1 → mitophagy; damaged mitochondria with oxidised Complex I removed → reduced DA-MAO-B H2O2 source); (4) ferritin H upregulation (Nrf2 → FTH1 → Fe3+ sequestration → Fenton ↓). TH-positive neuron preservation: −20–35% neuron loss in MPTP/6-OHDA spirulina pre-treatment models.
Neuroinflammation: Microglial NF-κB/NLRP3
Microglial neuroinflammation in Parkinsonism (M1 microglia; NF-κB → iNOS + TNF-α + IL-1β + IL-6 → dopaminergic neurotoxicity; NLRP3 (α-Syn oligomers → NLRP3 → IL-1β → ASC → caspase-1 → pro-IL-1β → IL-1β); iNOS/ONOO− → TH Tyr nitration → TH activity ↓ → reduced DA synthesis even in surviving neurons; TNF-α → neuronal TNFR1 → JNK/p38 → apoptosis; LRRK2 (Parkinson gene; Rab GTPase kinase; LRRK2-G2019S → excessive Rab8a/10 phosphorylation; LRRK2 → NF-κB → neuroinflammation positive feedback)): suppressed by spirulina: (1) Microglial NF-κB/IKKβ −30–45% → TNF-α −30–40%, IL-1β −25–35%, iNOS −30–45% (LPS/MPTP-stimulated BV-2/primary microglia models); (2) NLRP3 −25–35% (α-Syn-NLRP3 model; Nrf2-Txnip-NLRP3; NQO1-mtROS); (3) TH tyrosine nitration protection (eNOS-coupled NO (NO bioavailability ↑ by AMPK-eNOS) vs. iNOS-ONOO− (iNOS suppressed); net: ONOO− ↓ → TH Tyr nitration ↓ → TH activity preserved); (4) α-Synuclein aggregation: phycocyanobilin metal chelation (Cu2+/Fe2+) reduces DA-quinone-SNCA oxidation. TH activity −10–20% less loss; striatal DA −15–25% less depletion in MPTP models with spirulina pre-treatment.
MAO-B H2O2 and COMT SAM Support
MAO-B (monoamine oxidase B; outer mitochondrial membrane; FAD cofactor; DA → DOPAL (3,4-dihydroxyphenylacetaldehyde; electrophilic; SNCA-crosslinker) + H2O2; MAO-B also: PEA (phenylethylamine) catabolism; MPTP → MPP+ via MAO-B (paraquat-like; Complex I inhibitor; nigrostriatal lesion model); selegiline/rasagiline: MAO-B inhibitors; neuroprotective in PD) is modulated by spirulina: (1) MAO-B H2O2 mitochondrial sequestration: Nrf2-catalase +15–25% and GPx4 +20–30% in mitochondria → MAO-B H2O2 scavenging (H2O2 produced at OMM → Nrf2-peroxiredoxin 3/5 + GPx1 in matrix); (2) DOPAL detoxification: ALDH (aldehyde dehydrogenase; DOPAL → DOPAC; ALDH1A1 in SNc dopaminergic neurons; Nrf2 → ALDH1A1 induction +15–25% → faster DOPAL clearance → reduced SNCA crosslinking); (3) COMT (catechol-O-methyltransferase; SAM methyl donor; DA → 3-MT; NE → normetanephrine; spirulina Met → SAM cycle → SAM availability for COMT; B12/folate → Hcy remethylation → SAM pool maintained). MAO-B activity: spirulina does not directly inhibit MAO-B at physiological concentrations; mechanism is H2O2 scavenging not enzyme inhibition.
Clinical Outcomes in Dopamine/Catecholamine Biology
- TH-positive neurons (MPTP model; spirulina pre-treatment): −20–35% less loss
- Striatal DA (MPTP; 6-OHDA models): −15–25% less depletion
- Microglial NF-κB activation (LPS/MPTP): −30–45%
- TH nitration (ONOO− marker; SNc): −20–30%
- BH4 (dopaminergic/serotoninergic cofactor): +10–20%
- ALDH1A1 (DOPAL detoxification; Nrf2): +15–25%
Dosing and Drug Interactions
Neuroprotection/Parkinson risk reduction: 5–10g daily long-term (years); pre-symptomatic neuroprotective context; no therapeutic claim in established PD. L-DOPA/carbidopa (Sinemet; PD treatment): Spirulina supports residual TH/BH4 in surviving neurons; complementary upstream; spirulina does not substitute for exogenous L-DOPA; no pharmacological conflict; monitor for enhanced L-DOPA absorption (Tyr/aromatic AA competition at gut and BBB: protein in spirulina may slightly reduce L-DOPA absorption if taken simultaneously; separate by 1h). MAO-B inhibitors (selegiline/rasagiline): Spirulina H2O2 scavenging is downstream of MAO-B; MAO-B inhibitor reduces H2O2 source; complementary; not contraindicated. Dopamine agonists (pramipexole/ropinirole): Direct D2/D3 agonism; spirulina supports endogenous TH/DA; complementary; no conflict. Antipsychotics (D2 antagonists; haloperidol/risperidone): Spirulina TH/DA support does not antagonise D2 blockade; no direct pharmacological conflict but counteracts the intended D2 blockade direction in psychosis context; do not self-adjust. Summary: TH neurons −20–35% less loss, striatal DA −15–25% less depletion, microglia NF-κB −30–45%, BH4 +10–20%; dosing 5–10g daily. NK concern: low (separate from L-DOPA by 1h).